Publication | Open Access

A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart

NanomedicineEngineeringAllergyMedicineRespiratory InfectionPulmonary PharmacologyInfectious Respiratory DiseaseNative Ciprofloxacin CounterpartBiomedical EngineeringNew Therapeutic AvenuePharmacologyCiprofloxacin Nanoplex Exhibits